1. Asensi M, Medina I, Ortega A et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 2002; 33: 387–98.
2. Atmaca N, Atmaca HT, Kanici A, Anteplioglu T. Protective effect of resveratrol on sodium fluoride-induced oxidative stress, hepatotoxicity and neurotoxicity in rats. Food Chem Toxicol 2014; p. 245–78.
3. Aubin MC, Lajoie C, Clement R et al. Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol. J Pharmacol Exp Ther 2008; 325: 961–8.
4. Banerjee S, Bueso-Ramos C, Aggarwal BB. Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: Role of nuclear factor-kappa B, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 2002; 62: 4945–54.
5. Baur JA, Pearson KJ, Price NL et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444 (7117): 337–42.
6. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493–506.
7. Behbahani J, Thandapilly SJ, Louis XL, Huang Y et al. Resveratrol and small artery compliance and remodeling in the spontaneously hypertensive rat. Am J Hypertens 2010; 23 (12): 1273–8.
8. Bhat KP, Kosmeder JW, Pezzuto JM. Biological effects of resveratrol. Antioxid Redox Signal 2001; 3 (6): 1041–64.
9. Bhat KPL, Lantvit D, Christov K et al. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 2001; 
61 (20): 7456–63.
10. Bishayee A, Barnes KF, Bhatia D et al. Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine-initiated rat hepatocarcinogenesis. Cancer Prev Res 2010; 3: 753–63.
11. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000; 141 (10): 3657–67.
12. Brown VA, Patel KR, Viskaduraki M et al. Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics and Effect on the Insulin-like Growth Factor Axis. Cancer Res 2010; 70: 9003–11.
13. Chan V, Fenning A, Iyer A, Hoey A, Brown L. Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr Pharm Biotechnol 2011; 12: 429–36.
14. Chen CL, Yang HI, Yang WS et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135: 111–21.
15. Chen ML, Li J, Xiao WR et al. Protective effect of resveratrol against oxidative damage of UVA irradiated HaCaT cells. Jhong Nan Da Xue Xue Bao Yi Ban 2006; 31: 635–9.
16. Chen YR, Yi FF, Li XY et al. Resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction. Cardiovasc Drugs Ther 2008; 22: 479–85.
17. Csiszar A, Labinskyy N, Olson S et al. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 2009; 54: 668–75.
18. Das S, Mitrovsky G, Vasanthi HR et al. Antiaging Properties of a Grape-Derived Antioxidant Are Regulated by Mitochondrial Balance of Fusion and Fission Leading to Mitophagy Triggered by a Signaling Network of Sirt1-Sirt3-Foxo3-PINK1-PARKIN. Oxid Med Cell Longev 2014; 2014: 345105.
19. Dolinsky VW, Dyck JR. Calorie restriction and resveratrol in cardiovascular health and disease. Biochim Biophys Acta 2011; 1812: 1477–89.
20. Elliott PJ, Walpole S, Morelli L et al. Resveratrol/SRT501. Sirtuin SIRT1 activator, Treatment of type 2 diabetes. Drugs Fut 2009; 34: 291–5.
21. Frémont L. Biological effects of resveratrol. Life Sci 2000; 66 (8): 663–73.
22. Ghanim H, Sia CL, Abuaysheh S et al. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab 2010; 95 (9): 2–8.
23. Ghanim H, Sia CL, Korzeniewski K et al. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin Endocrinol Metab 2011; 96 (5): 1409–14.
24. Harper CE, Cook LM, Patel BB et al. Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats. Prostate 2009; 69: 1668–82.
25. Howitz KT, Bitterman KJ, Cohen HY et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425 (6954): 191–6.
26. Jimenez-Gomez Y, Mattison JA, Pearson KJ et al. Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, high-sugar diet. Cell Metab 2013; 18 (4): 533–45.
27. Kasdallah-Grissa A, Mornagui B, Aouani E et al. Resveratrol, a red wine polyphenol, attenuates ethanolinduced oxidative stress in rat liver. Life Sci 2007; 80: 1033–9.
28. Khan MM, Ahmad A, Ishrat T et al. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson’s disease. Brain Res 2010; 1328: 139–51.
29. Kim J, Cha Y-N, Surh Y-J. A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutation Research 2010; 690 (1–2): 12–23.
30. Kitada M, Koya D. Renal protective effects of resveratrol. Oxid Med Cell Longev 2013; p. 1155–60.
31. Kumar A, Negi G, Sharma SS. Neuroprotection by resveratrol in diabetic neuropathy: concepts & mechanisms. Curr Med Chem 2013; 20 (36): 4640–5.
32. Lee TH, Seo JO, Baek SH, Kim SY. Inhibi ory effects of resveratrol on melanin synthesis in ultraviolet B-induced pigmentation in Guinea pig skin. Biomol Ther (Seoul) 2014; 22 (1): 35–40.
33. Li H, Fostermann U. Resveratrol: a multifunctional compound improving endothelial function. Cardiovasc Drugs Ther 2009; 23: 425–9.
34. Li SY, Wang XB, Kong LY. Design, synthesis and biological evaluation of imine resveratrol derivatives as multi-targeted agents against Alzheimer's disease. Eur J Med Chem 2014; 71: 36–45.
35. Lin CJ, Chen TH, Yang LY, Shih CM. Resveratrol protects astrocytes against traumatic brain injury through inhibiting apoptotic and autophagic cell death. Cell Death Dis 2014; 5: 1147–50.
36. Lin HC, Chen YF, Hsu WH et al. Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model. Cancer Prev Res (Phila) 2012; 5 (7): 952–62.
37. Lin JF, Lin SM, Chih CL et al. Resveratrol reduces infarct size and improves ventricular function after myocardial ischemia in rats. Life Sci 2008; 83: 313–7.
38. Lu KT, Ko MC, Chen BY et al. Neuroprotective Effects of Resveratrol on MPTP-Induced Neuron Loss Mediated by Free Radical Scavenging. J Agric Food Chem 2008; 56: 6910–3.
39. Macarulla MT, Alberdi G, Gomez S et al. Effects of different doses of resveratrol on body fat and serum parameters in rats fed a hypercaloric diet. J Physiol Biochem 2009; 65: 369–76.
40. Mbimba T, Awale P, Bhatia D et al. Alteration of hepatic proinflammatory cytokines is involved in the resveratrol-mediated chemoprevention of chemically-induced hepatocarcinogenesis. Curr Pharm Biotechnol 2012; 13: 229–34.
41. Miatello R, Vazquez M, Renna N et al. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am J Hypertens 2005; 18: 864–70.
42. Mikstacka R, Rimando AM, Ignatowicz E. Antioxidant effect of trans-resveratrol, pterostilbene, quercetin and their combinations in human erythrocytes in vitro. Plant Foods Hum Nutr 2010; 65 (1): 57–63.
43. Mueller SO, Simon S, Chae K et al. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci 2004; 80 (1): 14–25.
44. Narayanan NK, Nargi D, Randolph C, Narayanan BA. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 2009; 125: 1–8.
45. Oomen CA, Farkas E, Roman V et al. Resveratrol preserves cerebrovascular density and cognitive function in aging mice. Front Aging Neurosci 2009; 1: 4–5.
46. Patel KR, Brown VA, Jones DJ et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 2010; 70: 7392–9.
47. Ranney A, Petro MS. Resveratrol protects spatial learning in middleaged C57BL/6 mice from effects of ethanol. Behav Pharmacol 2009; 20: 330–6.
48. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659–61.
49. Rege SD, Kumar S, Wilson DN et al. Resveratrol protects the brain of obese mice from oxidative damage. Oxid Med Cell Longev 2013; 
p. 419–20.
50. Saleh MC, Connell BJ, Saleh TM. Resveratrol preconditioning induces cellular stress proteins and is mediated via NMDA and estrogen receptors. Neuroscience 2010; 166: 445–54.
51. Scherz-Shouval R, Elazar Z. ROS, mitochondria and the regulation of autophagy. Trends in Cell Biology 2007; 17 (9): 422–7.
52. Seeni A, Takahashi S, Takeshita K et al. Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev 2008; 9: 7–14.
53. Shang J, Chen LL, Xiao FX et al. Resveratrol improves non-alcoholic fatty liver disease by activating AMPactivated protein kinase. Acta Pharmacol Sin 2008; 29: 698–706.
54. Shi Y, Camici GG, Lüscher TF. Cardiovascular determinants of life span. Pflügers Archiv 2010; 459 (2): 315–24.
55. Singleton RH, Yan HQ, Fellows-Mayle W, Dixon CE. Resveratrol attenuates behavioral impairments and reduces cortical and hippocampal loss in a rat controlled cortical impact model of traumatic brain injury. J Neurotrauma 2010; 27: 1091–9.
56. Sonmez U, Sonmez A, Erbil G et al. Neuroprotective effects of resveratrol against traumatic brain injury in immature rats. Neurosci Lett 2007; 420: 133–7.
57. Spanier G, Xu H, Xia N et al. Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). J Physiol Pharmacol 2009; 60: 111–6.
58. Sutra T, Oiry C, zay-Milhau J et al. Preventive effects of nutritional doses of polyphenolic molecules on cardiac fibrosis associated with metabolic syndrome: Involvement of osteopontin and oxidative stress. J Agric Food Chem 2008; 56: 11683–7.
59. Szkudelska K, Nogowski L, Szkudelski T. Resveratrol, a naturally occurring diphenolic compound, affects lipogenesis, lipolysis and the antilipolytic action of insulin in isolated rat adipocytes. J Steroid Biochem Mol Biol 2009; 113 (1–2): 17–24.
60. Taguchi K, Hida M, Matsumoto T et al. Effect of Short-term Polyphenol Treatment on Endothelial Dysfunction and Thromboxane A2 Levels in Streptozotocin-Induced Diabetic Mice. Biol Pharm Bull 2014; 37 (6): 1056–61.
61. Tangkeangsirisin W, Serrero G. Resveratrol in the chemoprevention and chemotherapy of breast cancer. In: Bagchi D, Preuss HG, eds. Phytopharmaceuticals in Cancer Chemoprevention. Boca Raton: CRC Press, 2005; p. 449–63.
62. Tessari P, Coracina A, Cosma A, Tiengo A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2009; 19: 291–302.
63. Thandapilly SJ, Wojciechowski P, Behbahani J et al. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens 2010; 23: 192–6.
64. Tilstra JS, Robinson J, Wang AR et al. NF-kB inhibition delays DNA damade-induced senescence and aging in mice. J Clin Invest 2012; 
122 (7): 2601–12.
65. Vang O, Ahmad N, Baile CA et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 2011; 6 (6): 198–200.
66. Vazquez-Agell M, Sacanella E, Tobias E et al. Inflammatory markers of atherosclerosis are decreased after moderate consumption of cava (sparkling wine) in men with low cardiovascular risk. J Nutr 2007; 137: 2279–84.
67. Vidavalur R, Otani H, Singal PK, Maulik N. Significance of wine and resveratrol in cardiovascular disease: French paradox revisited. Exp Clin Cardiol 2006; 11 (3): 217–25.
68. Wallerath T, Li H, Gödtel-Ambrust U et al. blend of polyphenolic compounds explains the stimulatory effect of red wine on human endothelial NO synthase. Nitric Oxide 2005; 12 (2): 97–104.
69. Wang Z, Zou J, Huang Y et al. Effect of resveratrol on platelet aggregation in vivo and in vitro. Chin Med J (Engl) 2002; 115 (3): 378–80.
70. Williams LD, Burdock GA, Edwards JA et al. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol 2009; 49: 2170–221.
71. Wong RH, Howe PR, Buckley JD et al. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis 2010; 3: 23-36; DOI:10.1016/j.numecd.
72. Xin P, Han H, Gao D et al. Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats. Food Chem Toxicol 2013; 52: 12–8.
73. Yang DL, Zhang HG, Xu YL et al. Resveratrol inhibits right ventricular hypertrophy induced by monocrotaline in rats. Clin Exp Pharmacol Physiol 2010; 37: 150–5.
74. Yu L, Sun ZJ, Wu SL, Pan CE. Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer. World J Gastroenterol 2003; 9: 2341–3.
75. Zhou HB, Chen JJ, Wang WX et al. Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol 2005; 11: 280–4.
76. Zhu X, Liu Q, Wang M et al. Activation of Sirt1 by resveratrol inhibits TNF-a induced inflammation in fibroblasts. PLoS One 2011; 6 (11): 3–8.
77. Wong RH, Howe PR, Buckley JD et al. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis 2011; 21 (11): 851–6.

________________________________________________

1. Asensi M, Medina I, Ortega A et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 2002; 33: 387–98.
2. Atmaca N, Atmaca HT, Kanici A, Anteplioglu T. Protective effect of resveratrol on sodium fluoride-induced oxidative stress, hepatotoxicity and neurotoxicity in rats. Food Chem Toxicol 2014; p. 245–78.
3. Aubin MC, Lajoie C, Clement R et al. Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol. J Pharmacol Exp Ther 2008; 325: 961–8.
4. Banerjee S, Bueso-Ramos C, Aggarwal BB. Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: Role of nuclear factor-kappa B, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 2002; 62: 4945–54.
5. Baur JA, Pearson KJ, Price NL et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444 (7117): 337–42.
6. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493–506.
7. Behbahani J, Thandapilly SJ, Louis XL, Huang Y et al. Resveratrol and small artery compliance and remodeling in the spontaneously hypertensive rat. Am J Hypertens 2010; 23 (12): 1273–8.
8. Bhat KP, Kosmeder JW, Pezzuto JM. Biological effects of resveratrol. Antioxid Redox Signal 2001; 3 (6): 1041–64.
9. Bhat KPL, Lantvit D, Christov K et al. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 2001; 
61 (20): 7456–63.
10. Bishayee A, Barnes KF, Bhatia D et al. Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine-initiated rat hepatocarcinogenesis. Cancer Prev Res 2010; 3: 753–63.
11. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000; 141 (10): 3657–67.
12. Brown VA, Patel KR, Viskaduraki M et al. Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics and Effect on the Insulin-like Growth Factor Axis. Cancer Res 2010; 70: 9003–11.
13. Chan V, Fenning A, Iyer A, Hoey A, Brown L. Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr Pharm Biotechnol 2011; 12: 429–36.
14. Chen CL, Yang HI, Yang WS et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135: 111–21.
15. Chen ML, Li J, Xiao WR et al. Protective effect of resveratrol against oxidative damage of UVA irradiated HaCaT cells. Jhong Nan Da Xue Xue Bao Yi Ban 2006; 31: 635–9.
16. Chen YR, Yi FF, Li XY et al. Resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction. Cardiovasc Drugs Ther 2008; 22: 479–85.
17. Csiszar A, Labinskyy N, Olson S et al. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 2009; 54: 668–75.
18. Das S, Mitrovsky G, Vasanthi HR et al. Antiaging Properties of a Grape-Derived Antioxidant Are Regulated by Mitochondrial Balance of Fusion and Fission Leading to Mitophagy Triggered by a Signaling Network of Sirt1-Sirt3-Foxo3-PINK1-PARKIN. Oxid Med Cell Longev 2014; 2014: 345105.
19. Dolinsky VW, Dyck JR. Calorie restriction and resveratrol in cardiovascular health and disease. Biochim Biophys Acta 2011; 1812: 1477–89.
20. Elliott PJ, Walpole S, Morelli L et al. Resveratrol/SRT501. Sirtuin SIRT1 activator, Treatment of type 2 diabetes. Drugs Fut 2009; 34: 291–5.
21. Frémont L. Biological effects of resveratrol. Life Sci 2000; 66 (8): 663–73.
22. Ghanim H, Sia CL, Abuaysheh S et al. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab 2010; 95 (9): 2–8.
23. Ghanim H, Sia CL, Korzeniewski K et al. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin Endocrinol Metab 2011; 96 (5): 1409–14.
24. Harper CE, Cook LM, Patel BB et al. Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats. Prostate 2009; 69: 1668–82.
25. Howitz KT, Bitterman KJ, Cohen HY et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425 (6954): 191–6.
26. Jimenez-Gomez Y, Mattison JA, Pearson KJ et al. Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, high-sugar diet. Cell Metab 2013; 18 (4): 533–45.
27. Kasdallah-Grissa A, Mornagui B, Aouani E et al. Resveratrol, a red wine polyphenol, attenuates ethanolinduced oxidative stress in rat liver. Life Sci 2007; 80: 1033–9.
28. Khan MM, Ahmad A, Ishrat T et al. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson’s disease. Brain Res 2010; 1328: 139–51.
29. Kim J, Cha Y-N, Surh Y-J. A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutation Research 2010; 690 (1–2): 12–23.
30. Kitada M, Koya D. Renal protective effects of resveratrol. Oxid Med Cell Longev 2013; p. 1155–60.
31. Kumar A, Negi G, Sharma SS. Neuroprotection by resveratrol in diabetic neuropathy: concepts & mechanisms. Curr Med Chem 2013; 20 (36): 4640–5.
32. Lee TH, Seo JO, Baek SH, Kim SY. Inhibi ory effects of resveratrol on melanin synthesis in ultraviolet B-induced pigmentation in Guinea pig skin. Biomol Ther (Seoul) 2014; 22 (1): 35–40.
33. Li H, Fostermann U. Resveratrol: a multifunctional compound improving endothelial function. Cardiovasc Drugs Ther 2009; 23: 425–9.
34. Li SY, Wang XB, Kong LY. Design, synthesis and biological evaluation of imine resveratrol derivatives as multi-targeted agents against Alzheimer's disease. Eur J Med Chem 2014; 71: 36–45.
35. Lin CJ, Chen TH, Yang LY, Shih CM. Resveratrol protects astrocytes against traumatic brain injury through inhibiting apoptotic and autophagic cell death. Cell Death Dis 2014; 5: 1147–50.
36. Lin HC, Chen YF, Hsu WH et al. Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model. Cancer Prev Res (Phila) 2012; 5 (7): 952–62.
37. Lin JF, Lin SM, Chih CL et al. Resveratrol reduces infarct size and improves ventricular function after myocardial ischemia in rats. Life Sci 2008; 83: 313–7.
38. Lu KT, Ko MC, Chen BY et al. Neuroprotective Effects of Resveratrol on MPTP-Induced Neuron Loss Mediated by Free Radical Scavenging. J Agric Food Chem 2008; 56: 6910–3.
39. Macarulla MT, Alberdi G, Gomez S et al. Effects of different doses of resveratrol on body fat and serum parameters in rats fed a hypercaloric diet. J Physiol Biochem 2009; 65: 369–76.
40. Mbimba T, Awale P, Bhatia D et al. Alteration of hepatic proinflammatory cytokines is involved in the resveratrol-mediated chemoprevention of chemically-induced hepatocarcinogenesis. Curr Pharm Biotechnol 2012; 13: 229–34.
41. Miatello R, Vazquez M, Renna N et al. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am J Hypertens 2005; 18: 864–70.
42. Mikstacka R, Rimando AM, Ignatowicz E. Antioxidant effect of trans-resveratrol, pterostilbene, quercetin and their combinations in human erythrocytes in vitro. Plant Foods Hum Nutr 2010; 65 (1): 57–63.
43. Mueller SO, Simon S, Chae K et al. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci 2004; 80 (1): 14–25.
44. Narayanan NK, Nargi D, Randolph C, Narayanan BA. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 2009; 125: 1–8.
45. Oomen CA, Farkas E, Roman V et al. Resveratrol preserves cerebrovascular density and cognitive function in aging mice. Front Aging Neurosci 2009; 1: 4–5.
46. Patel KR, Brown VA, Jones DJ et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 2010; 70: 7392–9.
47. Ranney A, Petro MS. Resveratrol protects spatial learning in middleaged C57BL/6 mice from effects of ethanol. Behav Pharmacol 2009; 20: 330–6.
48. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659–61.
49. Rege SD, Kumar S, Wilson DN et al. Resveratrol protects the brain of obese mice from oxidative damage. Oxid Med Cell Longev 2013; 
p. 419–20.
50. Saleh MC, Connell BJ, Saleh TM. Resveratrol preconditioning induces cellular stress proteins and is mediated via NMDA and estrogen receptors. Neuroscience 2010; 166: 445–54.
51. Scherz-Shouval R, Elazar Z. ROS, mitochondria and the regulation of autophagy. Trends in Cell Biology 2007; 17 (9): 422–7.
52. Seeni A, Takahashi S, Takeshita K et al. Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev 2008; 9: 7–14.
53. Shang J, Chen LL, Xiao FX et al. Resveratrol improves non-alcoholic fatty liver disease by activating AMPactivated protein kinase. Acta Pharmacol Sin 2008; 29: 698–706.
54. Shi Y, Camici GG, Lüscher TF. Cardiovascular determinants of life span. Pflügers Archiv 2010; 459 (2): 315–24.
55. Singleton RH, Yan HQ, Fellows-Mayle W, Dixon CE. Resveratrol attenuates behavioral impairments and reduces cortical and hippocampal loss in a rat controlled cortical impact model of traumatic brain injury. J Neurotrauma 2010; 27: 1091–9.
56. Sonmez U, Sonmez A, Erbil G et al. Neuroprotective effects of resveratrol against traumatic brain injury in immature rats. Neurosci Lett 2007; 420: 133–7.
57. Spanier G, Xu H, Xia N et al. Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). J Physiol Pharmacol 2009; 60: 111–6.
58. Sutra T, Oiry C, zay-Milhau J et al. Preventive effects of nutritional doses of polyphenolic molecules on cardiac fibrosis associated with metabolic syndrome: Involvement of osteopontin and oxidative stress. J Agric Food Chem 2008; 56: 11683–7.
59. Szkudelska K, Nogowski L, Szkudelski T. Resveratrol, a naturally occurring diphenolic compound, affects lipogenesis, lipolysis and the antilipolytic action of insulin in isolated rat adipocytes. J Steroid Biochem Mol Biol 2009; 113 (1–2): 17–24.
60. Taguchi K, Hida M, Matsumoto T et al. Effect of Short-term Polyphenol Treatment on Endothelial Dysfunction and Thromboxane A2 Levels in Streptozotocin-Induced Diabetic Mice. Biol Pharm Bull 2014; 37 (6): 1056–61.
61. Tangkeangsirisin W, Serrero G. Resveratrol in the chemoprevention and chemotherapy of breast cancer. In: Bagchi D, Preuss HG, eds. Phytopharmaceuticals in Cancer Chemoprevention. Boca Raton: CRC Press, 2005; p. 449–63.
62. Tessari P, Coracina A, Cosma A, Tiengo A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2009; 19: 291–302.
63. Thandapilly SJ, Wojciechowski P, Behbahani J et al. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens 2010; 23: 192–6.
64. Tilstra JS, Robinson J, Wang AR et al. NF-kB inhibition delays DNA damade-induced senescence and aging in mice. J Clin Invest 2012; 
122 (7): 2601–12.
65. Vang O, Ahmad N, Baile CA et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 2011; 6 (6): 198–200.
66. Vazquez-Agell M, Sacanella E, Tobias E et al. Inflammatory markers of atherosclerosis are decreased after moderate consumption of cava (sparkling wine) in men with low cardiovascular risk. J Nutr 2007; 137: 2279–84.
67. Vidavalur R, Otani H, Singal PK, Maulik N. Significance of wine and resveratrol in cardiovascular disease: French paradox revisited. Exp Clin Cardiol 2006; 11 (3): 217–25.
68. Wallerath T, Li H, Gödtel-Ambrust U et al. blend of polyphenolic compounds explains the stimulatory effect of red wine on human endothelial NO synthase. Nitric Oxide 2005; 12 (2): 97–104.
69. Wang Z, Zou J, Huang Y et al. Effect of resveratrol on platelet aggregation in vivo and in vitro. Chin Med J (Engl) 2002; 115 (3): 378–80.
70. Williams LD, Burdock GA, Edwards JA et al. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol 2009; 49: 2170–221.
71. Wong RH, Howe PR, Buckley JD et al. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis 2010; 3: 23-36; DOI:10.1016/j.numecd.
72. Xin P, Han H, Gao D et al. Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats. Food Chem Toxicol 2013; 52: 12–8.
73. Yang DL, Zhang HG, Xu YL et al. Resveratrol inhibits right ventricular hypertrophy induced by monocrotaline in rats. Clin Exp Pharmacol Physiol 2010; 37: 150–5.
74. Yu L, Sun ZJ, Wu SL, Pan CE. Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer. World J Gastroenterol 2003; 9: 2341–3.
75. Zhou HB, Chen JJ, Wang WX et al. Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol 2005; 11: 280–4.
76. Zhu X, Liu Q, Wang M et al. Activation of Sirt1 by resveratrol inhibits TNF-a induced inflammation in fibroblasts. PLoS One 2011; 6 (11): 3–8.
77. Wong RH, Howe PR, Buckley JD et al. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis 2011; 21 (11): 851–6.

Ю.Б.Успенская

ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России

________________________________________________

Yu.B.Uspenskaya